Genetic links to myopia in children and adolescents
Genetic Variants and Their Association With Myopia Risk, Progression, and Optimal Interventions in Children
Beijing Visionly Plus Eye Hospital · NCT07030153
The team will test whether specific gene variants influence myopia risk and progression in children and adolescents and whether those genes change how well treatments like low‑dose atropine drops, orthokeratology lenses, specialty glasses, or more outdoor time work.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 6 Years to 18 Years |
| Sex | All |
| Sponsor | Beijing Visionly Plus Eye Hospital (other) |
| Locations | 2 sites (Beijing and 1 other locations) |
| Trial ID | NCT07030153 on ClinicalTrials.gov |
What this trial studies
This observational study will collect DNA via oral swab from participants aged 6–18 and analyze myopia-related gene variants. Researchers will link genetic data to clinical measures such as spherical equivalent refraction and axial length change, and they will record participants' use of common myopia control measures (low-dose atropine, orthokeratology, specialized lenses, and time outdoors). The team will model gene-by-treatment interactions to see whether genetic profiles modify treatment response and disease progression. Finally, investigators will develop a genetic risk score intended to support personalized myopia prevention and treatment strategies.
Who should consider this trial
Good fit: Children and adolescents aged 6–18 with any spherical equivalent refraction whose parents or guardians consent to genetic testing and who do not have suspected genetic syndromes, other eye diseases, or prior refractive surgery are ideal candidates.
Not a fit: Patients with known genetic syndromes affecting the eye, other ocular diseases (for example glaucoma, cataracts, or retinal abnormalities), prior refractive surgery, or adults outside the 6–18 age range are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this work could allow prediction of which children are at higher risk and help match them to the most effective preventive or treatment strategies.
How similar studies have performed: Previous research has identified genetic variants and polygenic risk scores associated with myopia risk, but evidence for consistent gene-by-treatment interactions and routine clinical use remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 6-18 years. * Any Spherical equivalent refraction (SER) * Parental consent for genetic testing. Exclusion Criteria: * Suspected genetic syndromes (e.g., Stickler, Marfan). * Other eye diseases (e.g., glaucoma, cataracts, retinal abnormalities, strabismus). * Prior refractive surgery
Where this trial is running
Beijing and 1 other locations
- Beijing New Vision Eye Hospital — Beijing, China (RECRUITING)
- Beijing Visionly Plus Eye Hospital — Beijing, China (RECRUITING)
Study contacts
- Study coordinator: Lin Yang, M.D.
- Email: roc001cn@gmail.com
- Phone: +86-17898805125
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Myopia, genetic, intervention